PDCD1 and neoplasm: In the KRASG12C CT26 syngeneic mouse model, AMG510 treatment has been found to induce a pro-inflammatory microenvironment by enhancing the tumor infiltrated CD8+ T cells, DCs, NKs, etc., and it exerted extended anti-tumor efficacy when combined with anti-PD-1[133].